Former Postdoctoral Fellow, Integrative Neurobiology Section
ContactTriad Technology Center
333 Cassell Drive
Baltimore, MD 21224
Ph.D. – Pharmacology at Department of Pharmacology, Universidade Federal de Santa Catarina – UFSC, Brazil (2016)
Doctoral internship - Facultat de Medicina i Ciències de la Salut, Unitat de Farmacologia, Universitat de Barcelona – UB, Spain (2015)
M.Sc. - Pharmacology at Department of Pharmacology, Universidade Federal de Santa Catarina – UFSC, Brazil (2012)
B.Pharm. - Faculty of Pharmacy, Universidade Luterana do Brasil – ULBRA, Brazil (2006)
Paulo started his research career in 2004 at the Laboratory of Pharmacology (Univ. Luterana do Brasil, Brazil) as an undergrad trainee, where he was involved in behavioral psychopharmacology screening of natural compounds. In 2010, he began his Master’s in Pharmacology (Univ. Federal de Santa Catarina, Brazil) at the Laboratory of Neurodegenerative Disease, where he participated in several studies using Parkinson’s disease animal models focusing on behavioral analysis and pharmacological screening of preventive drugs. His Ph.D. thesis demonstrated the therapeutic effects of angiotensin II type 1 receptor (AT1R) antagonism in animal models of aging and Parkinson’s disease. He has also shown that AT1R can exert synergistic effects with adenosine A2A receptors (A2AR), by GPCR heteromerization.
His current project seeks to understand the role of heteromers of dopamine, serotonin and opioid receptors as targets for substance use disorders. Using advanced biophysical techniques, such as bimolecular fluorescence complementation and bioluminescence resonance energy transfer, in mammalian transfected cells. Also, the results obtained with these in vitro assays will be investigated in- and ex-vivo models in rodents. The final goal is to identify GPCR heteromer-based treatments for substance use disorders
In: Mol Neurobiol, 2018, ISSN: 1559-1182 (Electronic); 0893-7648 (Linking).
In: Mol Genet Metab, 2018, ISSN: 1096-7206 (Electronic); 1096-7192 (Linking).
In: Toxicology, vol. 387, pp. 67–80, 2017, ISSN: 1879-3185 (Electronic); 0300-483X (Linking).
In: Brain Res, vol. 1663, pp. 78–86, 2017, ISSN: 1872-6240 (Electronic); 0006-8993 (Linking).
In: Sci Rep, vol. 7, no. 1, pp. 1857, 2017, ISSN: 2045-2322 (Electronic); 2045-2322 (Linking).